How good is allogeneic transplantation for high-risk patients with AML?

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 2, 2006, Pages 329-332

  Messner, Hans A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Allogeneic BMT; AML; Risk factors

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOTRANSPLANTATION; CANCER THERAPY; CLINICAL TRIAL; CYTOGENETICS; DATA ANALYSIS; DISEASE COURSE; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALIGNANT NEOPLASTIC DISEASE; MYELODYSPLASIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT PLANNING;

AGE FACTORS; BONE MARROW TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MONITORING, PHYSIOLOGIC; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33644524107     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.11.007     Document Type: Review

References (17)

1. D. Grimwade H. Walker F. Oliver et. al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties Blood 92 1998 2322-2333
2. M.L. Slovak K.J. Kopecky P.A. Cassileth et. al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A southwest oncology group/eastern cooperative oncology group study Blood 96 2000 4075-4083
3. C. Schoch W. Kern S. Schnittger et. al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups Haematologica 89 2004 1082-1090
4. J.O. Moore S.L. George R.K. Dodge et. al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and leukemia group B study 9222 Blood 105 2005 3420-3427
5. E. Tavernier Q.H. Le M. Elhamri X. Thomas Salvage therapy in refractory acute myeloid leukemia: Prediction of outcome based on analysis of prognostic factors Leuk Res 27 2003 205-214
6. H.C. Fung A. Stein M. Slovak et. al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: Impact of cytogenetic characteristics on transplantation outcome Biol Blood Marrow Transplant 9 2003 766-771
7. Y. Chalandon M.J. Barnett D.E. Horsman et. al. Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission Biol Blood Marrow Transplant 8 2002 435-443
8. S. Suciu F. Mandelli T. de Witte et. al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): An intention-to-treat analysis of the EORTC/ GIMEMAAML-10 trial Blood 102 2003 1232-1240
9. J. Reiffers A.M. Stoppa M. Attal et. al. Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: The BGMT 87 study Leukemia 10 1996 1874-1882
10. S. Keating T. de Witte S. Suciu et. al. The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European organization for research and treatment of cancer. Gruppo italiano malattie ematologiche maligne dell'adulto Br J Haematol 102 1998 1344-1353
11. A.K. Burnett K. Wheatley A.H. Goldstone et. al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial Br J Haematol 118 2002 385-400
12. M. Yanada K. Matsuo N. Emi T. Naoe Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: A metaanalysis Cancer 103 2005 1652-1658
13. H. Kiyoi T. Naoe Y. Nakano et. al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 93 1999 3074-3080
14. S. Schnittger C. Schoch M. Dugas et. al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease Blood 100 2002 59-66
15. D.A. Breems W.L. van Putten P.C. Huijgens et. al. Prognostic index for adult patients with acute myeloid leukemia in first relapse J Clin Oncol 23 2005 1969-1978
16. H. Bertz K. Potthoff J. Finke Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia J Clin Oncol 21 2003 1480-1484
17. A. Spyridonidis H. Bertz G. Ihorst et. al. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or =60 years) with active myeloid malignancies Blood 105 2005 4147-4148